Post on 18-Feb-2018
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 1/55
DyslipidemiasDyslipidemias
Atherosclerosis AtherosclerosisSnejana Vetrila MD PhDSnejana Vetrila MD PhD
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 2/55
DislipidemiaDislipidemia
Total serum cholesterol greater than 200Total serum cholesterol greater than 200mg/dLmg/dL (!(!0/"!0/"! mmol/l#mmol/l#
LDL cholesterol greater than $00 mg/dLLDL cholesterol greater than $00 mg/dL%DL cholesterol less than "0 mg/dL%DL cholesterol less than "0 mg/dL
Triglycerides greater than $0 mg/dLTriglycerides greater than $0 mg/dL
Lipoprotein(a# less than &0 mg/dLLipoprotein(a# less than &0 mg/dL
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 3/55
Lipoproteins and ApolipoproteinsLipoproteins and Apolipoproteins
'steriied cholesterol and triglycerides are'steriied cholesterol and triglycerides areinsolu)le in )lood and are transported ininsolu)le in )lood and are transported inplasma )y lipoproteinsplasma )y lipoproteins**
high+density lipoprotein (%DL# cholesterol,high+density lipoprotein (%DL# cholesterol,lo-+density lipoprotein (LDL# cholesterollo-+density lipoprotein (LDL# cholesterol
.ery+lo- density lipoproteins (VLDL#.ery+lo- density lipoproteins (VLDL#
intermediate+density lipoproteins (DL#intermediate+density lipoproteins (DL# chylomicronschylomicrons
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 4/55
The density and sie+distri)ution o theThe density and sie+distri)ution o themajor classes o lipoprotein particlesmajor classes o lipoprotein particles
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 5/55
LLipoprotein meta)olism has )een separatedipoprotein meta)olism has )een separatedinto e1ogenous and endogenous path-aysinto e1ogenous and endogenous path-ays
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 6/55
Dietary FatsDietary Fats
Dietary ats are processed )y pancreaticDietary ats are processed )y pancreatic
lipase to atty acids to allo-lipase to atty acids to allo- (permite#(permite#
a)sorption across the intestinal epithelium,a)sorption across the intestinal epithelium, -here they are re+esteriied to triglycerides-here they are re+esteriied to triglycerides
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 7/55
Dietary CholesterolDietary Cholesterol
A)sorption o dietary or recirculated )iliary A)sorption o dietary or recirculated )iliarycholesterol is largely )y diusion across thecholesterol is largely )y diusion across theintestinal )rush )order in the jejunumintestinal )rush )order in the jejunum
It is important to recognize that only half ofIt is important to recognize that only half ofthe intestinal cholesterol is absorbed, mainlythe intestinal cholesterol is absorbed, mainlyin the form of recirculated biliary cholesterol,in the form of recirculated biliary cholesterol,while less than 30 comes from dietarywhile less than 30 comes from dietary
cholesterolcholesterol This e1plains -hy limiting the intae o dietaryThis e1plains -hy limiting the intae o dietarycholesterol oten sho-s only modestcholesterol oten sho-s only modestimpro.ement in cholesterol le.elsimpro.ement in cholesterol le.els
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 8/55
LDL and !DLLDL and !DL
are continuously remodeled in plasma, aare continuously remodeled in plasma, acomple1 process in.ol.ing enymes,comple1 process in.ol.ing enymes,transer proteins, and receptorstranser proteins, and receptors
This allo-s LDL to act as a transporter oThis allo-s LDL to act as a transporter ocholesterol rom the li.er to target tissues,cholesterol rom the li.er to target tissues,-hile %DL carries out the opposite-hile %DL carries out the opposite
unctionunction
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 9/55
"enetics"enetics
only a e- patients ha.e no-nonly a e- patients ha.e no-nmonogenic deects, the most common omonogenic deects, the most common o-hich is amilial hypercholesterolemia-hich is amilial hypercholesterolemia(3%#, occurring in $ in 00 patients(3%#, occurring in $ in 00 patients
aa)normal lipid le.els de.elop in most)normal lipid le.els de.elop in mostpatients aterpatients ater weight gain, with sedentaryweight gain, with sedentarylifestyle, or in the presence of otherlifestyle, or in the presence of other
disorders, such as diabetes mellitus anddisorders, such as diabetes mellitus andrenal or thyroid diseaserenal or thyroid disease
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 10/55
!istory!istory
lipid proiles o)tained )eore medications -erelipid proiles o)tained )eore medications -erestartedstarted
response to the initial drug and any ad.erseresponse to the initial drug and any ad.erseeects including myalgias and a)normal li.ereects including myalgias and a)normal li.erunction testsunction tests
amily history o early coronary disease oramily history o early coronary disease ordyslipidemia suggests a genetic componentdyslipidemia suggests a genetic component
recent -eight gain or -eight loss should also )erecent -eight gain or -eight loss should also )erecordedrecorded
screen or regular alcohol use as it a re4uentscreen or regular alcohol use as it a re4uentcause o ele.ated triglycerides and -eight gaincause o ele.ated triglycerides and -eight gain
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 11/55
#hysical $%amination#hysical $%amination
ocus on the cardio.ascular systemocus on the cardio.ascular system
)ut maniestations o meta)olic diseases)ut maniestations o meta)olic diseases
are oten missed and include a)dominalare oten missed and include a)dominalpain (enlarged li.er or spleen, gallstones,pain (enlarged li.er or spleen, gallstones,pancreatitis#pancreatitis#
corneal changes, and tendon or erupti.ecorneal changes, and tendon or erupti.e1anthomas1anthomas
truncal o)esity, lipodystrophy, acanthosistruncal o)esity, lipodystrophy, acanthosis
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 12/55
Laboratory AssessmentLaboratory Assessment
LLipid proile should )e o)tained in allipid proile should )e o)tained in alladults 20 years o age or older atadults 20 years o age or older at
least once e.ery yearsleast once e.ery years
The Third 5eport o the 6ational 7holesterol 'ducationThe Third 5eport o the 6ational 7holesterol 'ducationProgram (67'P# '1pert Panel on Detection, '.aluation,Program (67'P# '1pert Panel on Detection, '.aluation,and Treatment o %igh 8lood 7holesterol in Adults (Adultand Treatment o %igh 8lood 7holesterol in Adults (Adult
Treatment Panel (ATP# #Treatment Panel (ATP# #
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 13/55
&asic screening should also include&asic screening should also include
thyroid unction studiesthyroid unction studies li.er unction studies, asting glucose,li.er unction studies, asting glucose,)aseline creatine inase, and urine analysis)aseline creatine inase, and urine analysis
8aseline uric acid le.els may )e needed8aseline uric acid le.els may )e needed)eore starting niacin therapy)eore starting niacin therapy
to estimate cardio.ascular ris, such asto estimate cardio.ascular ris, such as
apo 8, homocysteine, 7+reacti.e proteinapo 8, homocysteine, 7+reacti.e protein(75P#, and lipoprotein+associated(75P#, and lipoprotein+associatedphospholipase A2 (Lp+PLA2#phospholipase A2 (Lp+PLA2#
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 14/55
Vascular studies toolsVascular studies tools
anle+)rachial+inde1 (A8#anle+)rachial+inde1 (A8#
carotid intima+medial thicness (MT#carotid intima+medial thicness (MT#
coronary artery calcium scores (7A7S#coronary artery calcium scores (7A7S#coronary angiography )y computedcoronary angiography )y computedtomography (7TA# estimate su)clinicaltomography (7TA# estimate su)clinical
.ascular disease )urden.ascular disease )urden
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 15/55
'pidemiologic studies suggest that'pidemiologic studies suggest thatin middle+aged menin middle+aged men
higher LDL (each $ mg/dLhigher LDL (each $ mg/dLincrease is associated -ith a $9increase is associated -ith a $9ris increase#ris increase#
lo-er %DL (each $ mg/dLlo-er %DL (each $ mg/dLdecrease is associated -ith a 29decrease is associated -ith a 29ris increase#ris increase#
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 16/55
3redricson, Lees3redricson, Lees andand Le.yLe.y classiicationclassiication
"enetic,"enetic, familfamily formsy forms 7hilomicroni +7hilomicroni + tipul Itipul I 8eta lipoproteine (LDL# +8eta lipoproteine (LDL# + tipultipul IIIIaa 8eta (LDL# :i pre+)eta (VLDL# lipoproteine +8eta (LDL# :i pre+)eta (VLDL# lipoproteine + tipultipul IIIIbb 8oala )eta e1tins; (<)road )eta= disease# +8oala )eta e1tins; (<)road )eta= disease# + tipul IIItipul III Pre+)eta lipoproteine (VLDL# +Pre+)eta lipoproteine (VLDL# + tipul I'tipul I' 7hilomicroni :i VLDL +7hilomicroni :i VLDL + tipul 'tipul '
ac(uiredac(uired (ar; transmitere ereditar; documentat;#(ar; transmitere ereditar; documentat;#
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 17/55
DislipidemiaDislipidemia
%ypercholesterolemia%ypercholesterolemia
%ypertrigliceridemia%ypertrigliceridemia
Mi1edMi1ed
C
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 18/55
)otal)otal CholeterolCholeterol,, mgdLmgdL
Desira)le > 200Desira)le > 200
8orderline high 200?2&@8orderline high 200?2&@
%igh 2"0%igh 2"0
!DL Cholesterol!DL Cholesterol
Lo- > "0Lo- > "0
%igh 0%igh 0LDLLDL CholesterolCholesterol
BptimalBptimal** > $00> $00
6ear or a)o.e optimal $00?$2@6ear or a)o.e optimal $00?$2@
8orderline high $&0?$@8orderline high $&0?$@ %igh$0?$C@%igh$0?$C@
Very highVery high $@0$@0
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 19/55
Major 5is 3actors (e1clusi.e o LDL+Major 5is 3actors (e1clusi.e o LDL+cholesterol#cholesterol#
7igarette smoing7igarette smoing%ypertension ()lood pressure $"0/@0 mm%ypertension ()lood pressure $"0/@0 mm%g or on antihypertensi.e medication#%g or on antihypertensi.e medication#
Lo- %DL+7 (> "0 mg/dL#Lo- %DL+7 (> "0 mg/dL#3amily history o premature 7AD (7AD in3amily history o premature 7AD (7AD inmale irst+degree relati.e > years 7ADmale irst+degree relati.e > years 7AD
in emale irst+degree relati.e > years#in emale irst+degree relati.e > years# Age (men " years -omen years# Age (men " years -omen years#
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 20/55
!ypertriglyceridemia!ypertriglyceridemia
%%ypertriglyceridemia is not the primary lipidypertriglyceridemia is not the primary lipidtarget in patients -ith 7ADtarget in patients -ith 7AD
'le.ated triglycerides are common (more'le.ated triglycerides are common (more
than 29 o population# and otenthan 29 o population# and otenassociated -ith secondary causes (such asassociated -ith secondary causes (such aso)esity dia)etes renal disease theo)esity dia)etes renal disease the
meta)olic syndrome and a num)er ometa)olic syndrome and a num)er odrugs, including protease inhi)itors anddrugs, including protease inhi)itors andestrogens#estrogens#
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 21/55
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 22/55
!ypertriglyceridemia!ypertriglyceridemia
)reatment)reatment
7hanges in liestyle or treatment o the7hanges in liestyle or treatment o theprimary disease process may )e suicientprimary disease process may )e suicientto reduce triglyceride le.elsto reduce triglyceride le.els
high car)ohydrate intae and alcohol usehigh car)ohydrate intae and alcohol useare re4uently o.erlooedare re4uently o.erlooed
statin therapy in com)ination -ith otherstatin therapy in com)ination -ith otherlipid+lo-ering drugs such as i)rates,lipid+lo-ering drugs such as i)rates,niacin, or omega+& atty acidsniacin, or omega+& atty acids
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 23/55
!DL Cholesterol!DL Cholesterol
Lo- %DL is a strong predictor o 7AD andLo- %DL is a strong predictor o 7AD andincreased cardio.ascular mortalityincreased cardio.ascular mortality
Lo- %DL is oten part o the meta)olicLo- %DL is oten part o the meta)olicsyndrome and associated -ith ele.atedsyndrome and associated -ith ele.atedtriglyceridestriglycerides
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 24/55
Major 7auses o 5educed Serum %DLMajor 7auses o 5educed Serum %DL7holesterol7holesterol
7igarette smoing7igarette smoing B)esityB)esityLac o e1erciseLac o e1ercise
Androgenic and related steroids Androgens Androgenic and related steroids AndrogensProgestational agentsProgestational agents Ana)olic steroids Ana)olic steroids Adrenergic+)locing agents Adrenergic+)locing agents
%ypertriglyceridemia%ypertriglyceridemiaEenetic actorsEenetic actorsPrimary hypoalphalipoproteinemiaPrimary hypoalphalipoproteinemia
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 25/55
Dietary *odificationDietary *odification
Very lo-+at diets such as the Dean BrnishVery lo-+at diets such as the Dean BrnishDiet, the Pritiin Diet, and most .egetarianDiet, the Pritiin Diet, and most .egetariandiets can e.en lo-er %DL cholesteroldiets can e.en lo-er %DL cholesterol
n contrast, a diet rich inn contrast, a diet rich inmonounsaturated ats such as themonounsaturated ats such as theMediterranean or South 8each Diets mayMediterranean or South 8each Diets may
increase or maintain %DL le.elsincrease or maintain %DL le.els
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 26/55
$%ercise$%ercise
Physical inacti.ity is a modiia)le ris actor, andPhysical inacti.ity is a modiia)le ris actor, anddaily e1ercise is recommended as an adjunct todaily e1ercise is recommended as an adjunct todietary modiication or the initial treatment odietary modiication or the initial treatment o
hyperlipidemiahyperlipidemiaTThe )eneits o com)ined resistance and aero)iche )eneits o com)ined resistance and aero)ice1ercise ha.e )ecome apparent and should )ee1ercise ha.e )ecome apparent and should )eencouraged in e.ery patientencouraged in e.ery patient
Faling o at least 000 steps daily or a goalFaling o at least 000 steps daily or a goale1ercise o $00 calories -eely should )ee1ercise o $00 calories -eely should )erecommended to all patientsrecommended to all patients
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 27/55
#harmacologic )herapy#harmacologic )herapy
+mega3 Fatty Acids -Fish +il.+mega3 Fatty Acids -Fish +il.
can used in com)ination -ith statins,can used in com)ination -ith statins,
i)rates, and niacin -ithout signiicant sidei)rates, and niacin -ithout signiicant side
eects, )ut re4uently increase LDL ineects, )ut re4uently increase LDL in
higher doseshigher doses
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 28/55
&ile Acid /e(uestrants&ile Acid /e(uestrants
The )ile acid+)inding resinsThe )ile acid+)inding resinscholestyramine, colestipol, andcholestyramine, colestipol, andcolese.elam (Fel7hol# are used ascolese.elam (Fel7hol# are used as
second+line therapy and in com)inationsecond+line therapy and in com)ination-ith other agents to treat-ith other agents to treathypercholesterolemia -ithout concurrenthypercholesterolemia -ithout concurrent
hypertriglyceridemiahypertriglyceridemia
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 29/55
Cholesterol Absorption InhibitorsCholesterol Absorption Inhibitors
'etimi)e, the irst drug in this class,'etimi)e, the irst drug in this class,inhi)its the a)sorption o cholesterol andinhi)its the a)sorption o cholesterol andphytosterols through the intestinal )rushphytosterols through the intestinal )rush
)order and interrupts the enterohepatic)order and interrupts the enterohepaticrecirculation o sterols rom )ile!recirculation o sterols rom )ile!
'etimi)e lo-ers LDL )ut does not aect'etimi)e lo-ers LDL )ut does not aect
triglyceridestriglycerides
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 30/55
FibratesFibrates
3i)rates reduce plasma triglycerides and3i)rates reduce plasma triglycerides andconcurrently raise %DL cholesterol le.elsconcurrently raise %DL cholesterol le.els
Their eects on LDL cholesterol are lessTheir eects on LDL cholesterol are lessmared and more .aria)lemared and more .aria)le
3i)rates are irst+line therapy to reduce the3i)rates are irst+line therapy to reduce theris o pancreatitis in patients -ith .eryris o pancreatitis in patients -ith .eryhigh le.els o plasma triglycerideshigh le.els o plasma triglycerides
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 31/55
iaciniacin
a -ater+solu)le .itamin, has )een sho-na -ater+solu)le .itamin, has )een sho-nto lo-er VLDL and LDL le.els and toto lo-er VLDL and LDL le.els and toincrease %DL le.els -hen gi.en in largeincrease %DL le.els -hen gi.en in large
dosesdoses t is gi.en either as a long+acting ormt is gi.en either as a long+acting ormonce daily or as regular niacin in highonce daily or as regular niacin in high
doses three times dailydoses three times daily ts use is oten limited )y side eects andts use is oten limited )y side eects andpatient noncompliancepatient noncompliance
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 32/55
/tatins/tatins
7oA reductase inhi)itors produce su)stantial7oA reductase inhi)itors produce su)stantialreduction in le.els o LDL cholesterol and, to areduction in le.els o LDL cholesterol and, to alesser e1tent, triglyceride le.elslesser e1tent, triglyceride le.els
n modest daily doses, statins reduce total andn modest daily doses, statins reduce total andLDL cholesterol at a rate o $?09 and mayLDL cholesterol at a rate o $?09 and mayreduce triglycerides )y $0?&09reduce triglycerides )y $0?&09
''ecti.e as monotherapy, statin inhi)itors can )eecti.e as monotherapy, statin inhi)itors can )ecom)ined -ith eetimi)e -hen LDL goals are notcom)ined -ith eetimi)e -hen LDL goals are noto)tained, or -ith i)rates or niacin or an additi.eo)tained, or -ith i)rates or niacin or an additi.eeect on triglycerideseect on triglycerides
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 33/55
Statins ha.e re.olutionied the treatmentStatins ha.e re.olutionied the treatmento hyperlipidemia )y their potency, eicacy,o hyperlipidemia )y their potency, eicacy,
and tolera)ility and ha.e e.ol.ed into irst+and tolera)ility and ha.e e.ol.ed into irst+line therapy or most orms oline therapy or most orms ohyperlipidemiahyperlipidemia
6umerous studies -ith statins in.ol.ing6umerous studies -ith statins in.ol.ingprimary and secondary pre.ention o 7ADprimary and secondary pre.ention o 7ADha.e demonstrated a reduction in 7ADha.e demonstrated a reduction in 7ADe.ents, 7AD mortality, stroe, ande.ents, 7AD mortality, stroe, and
mortality rom all other causesmortality rom all other causes
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 34/55
n addition, statins e1hi)it pleiotropic eectsn addition, statins e1hi)it pleiotropic eects
)eyond the lo-ering o LDL cholesterol le.els)eyond the lo-ering o LDL cholesterol le.elsand are postulated to possess antiinlammatoryand are postulated to possess antiinlammatoryproperties, contri)ute to coronary pla4ueproperties, contri)ute to coronary pla4uesta)iliation, and impro.e endothelial cellsta)iliation, and impro.e endothelial cell
unction, conditions that are increasinglyunction, conditions that are increasinglyrecognied as emerging areas o therapy or therecognied as emerging areas o therapy or thetreatment o 7ADtreatment o 7AD
Statins may also play a role in the treatment oStatins may also play a role in the treatment ocongesti.e heart ailure, osteoporosis, sepsis,congesti.e heart ailure, osteoporosis, sepsis,aortic stenosis, and chronic idney diseaseaortic stenosis, and chronic idney disease
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 35/55
Statins are contraindicatedStatins are contraindicated
in pregnancy and lactationin pregnancy and lactation
nn the coadministration -ith immunosuppressi.e drugs,the coadministration -ith immunosuppressi.e drugs,i)rates, niacin, macrolides, calcium channel )locers,i)rates, niacin, macrolides, calcium channel )locers,and etoconaoles that all may increase the ris oand etoconaoles that all may increase the ris o
rha)domyolysisrha)domyolysis Although statins are -ell tolerated, $09 o patients Although statins are -ell tolerated, $09 o patientse1perience some degree o side eects! Asymptomatice1perience some degree o side eects! Asymptomaticand transient ele.ation in li.er unction studies occur inand transient ele.ation in li.er unction studies occur inup to 29 o patients! t is recommended that treatmentup to 29 o patients! t is recommended that treatment)e stopped i li.er unction studies increase to three)e stopped i li.er unction studies increase to threetimes the upper limit o normal! Values usually re.ert totimes the upper limit o normal! Values usually re.ert to)aseline ater discontinuation o treatment!)aseline ater discontinuation o treatment!
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 36/55
Lipid $ffects of onLipidLoweringLipid $ffects of onLipidLowering
DrugsDrugs Selecti.e $+)locers ha.e )een sho-n to reduceSelecti.e $+)locers ha.e )een sho-n to reducetriglycerides and increase %DL to a modesttriglycerides and increase %DL to a modestdegree and are neutral -ith regard to glucosedegree and are neutral -ith regard to glucose
controlcontrolestrogens in postmenopausal -omen can lo-erestrogens in postmenopausal -omen can lo-erLDL and total cholesterol -ith additionalLDL and total cholesterol -ith additionalincreases in %DLincreases in %DL
The selecti.e estrogen receptor modulatorThe selecti.e estrogen receptor modulatorralo1iene also lo-ers total and LDL cholesterol,ralo1iene also lo-ers total and LDL cholesterol,al)eit -ith much lo-er ris o side eectsal)eit -ith much lo-er ris o side eects
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 37/55
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 38/55
AtherosclerosisAtherosclerosis
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 39/55
DeinitionDeinition
Atherosclerosis is a c Atherosclerosis is a chronic, progressi.e,hronic, progressi.e,multiocal disease o the .essel -all intimamultiocal disease o the .essel -all intima-ithin large elastic arteries and-ithin large elastic arteries and
large/medium sied muscular arterieslarge/medium sied muscular arteries
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 40/55
Atheroma or pla4ue ormation Atheroma or pla4ue ormation Gntimal thicening (smooth muscle cellGntimal thicening (smooth muscle cell
prolieration#prolieration# Lipid accumulation (monocyteLipid accumulation (monocytephagocytosis#phagocytosis#
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 41/55
%istology o a normal artery%istology o a normal artery
http://www.siumed.edu/~dking2/crr/cvguide
The medial layercontributes most to themechanical strength of anartery
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 42/55
42
AT%'5BS7L'5BT7 PLAHI' AT%'5BS7L'5BT7 PLAHI'
N!"#$ #!T%!&N!"#$ #!T%!& #T'%!()$%!T*)#T'%!()$%!T*)
+$#,-%+$#,-%
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 43/55
4
AtherosclerosisAtherosclerosis
7BMMB6 5SJ 3A7TB5S A5'7BMMB6 5SJ 3A7TB5S A5'
$ 675'AS6E AE'$ 675'AS6E AE'
2 MAL' E'6D'52 MAL' E'6D'5 & 3AMLK %STB5K& 3AMLK %STB5K
" E'6'T7 A86B5MALT5S" E'6'T7 A86B5MALT5S
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 44/55
44
#+)$)IAL C+)1+LLA&L$ 1I/2 FAC)+1/#+)$)IAL C+)1+LLA&L$ 1I/2 FAC)+1/
$ %KP'5LPD'MA$ %KP'5LPD'MA
2 %KP'5T'6TB62 %KP'5T'6TB6
& DA8'T'S M'LLTIS& DA8'T'S M'LLTIS
" 7EA5'TT' SMBJ6E" 7EA5'TT' SMBJ6E
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 45/55
4
AtherosclerosisAtherosclerosis
BT%'5 5SJ 3A7TB5S A5'BT%'5 5SJ 3A7TB5S A5'
$ B8'STK$ B8'STK
2 P%KS7AL 6A7TVTK2 P%KS7AL 6A7TVTK
& ST5'SS& ST5'SS
" PBSTM'6BPBISAL 'ST5BE'6 D'37'67K" PBSTM'6BPBISAL 'ST5BE'6 D'37'67K
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 46/55
40
AtherosclerosisAtherosclerosis
BT%'5 5SJ 3A7TB5S A5'BT%'5 5SJ 3A7TB5S A5' %E% 7A58B%KD5AT' 6TAJ' %E% 7A58B%KD5AT' 6TAJ'
LPBP5BT'6S LPBP5BT'6S
!A1D$$D 4/A)41A)$D FA) I)A2$ !A1D$$D 4/A)41A)$D FA) I)A2$
5 C!LA*6DIA #$4*+IA5 C!LA*6DIA #$4*+IA
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 47/55
The maor cellular events in
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 48/55
%ndothelial cell "onocyte "acrophage
1oam cell (mooth musclecell
Internalelasticlamina
Vessellumen
1.Endothelialpermeability
4. SMCmigration
2. Monocyteadhesionandtransmigration
Increasedstifness
3.Macrophagetransormation into oam
cells
The maor cellular events inthe progression of
atherosclerosis
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 49/55
!asic processes in ather
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 50/55
Stage I
monocyte adhesion"mig
Stage IIoam cells #lipid
containingmacrophages$ inintima
Stage IIIappearance o e%tracell
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 51/55
Stage IVCore ormation#e%tracellular lipid
coalescing into thecenter o the pla&ue$
Stage V'ibrous Cap and Core ormation#ully ormed lipid core and (ell de)elopedcap o *brous tissue seperating the core
rom the lumen$
Stage VI+hrombosis
3B5MS B33B5MS B3
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 52/55
2
3B5MS B33B5MS B3 AT%'5BS7L'5BSS AT%'5BS7L'5BSS
7'5'85AL A5T'5'S 6I5K7'5'85AL A5T'5'S 6I5K
7A5DA7 A5T'5'S 6I5K7A5DA7 A5T'5'S 6I5K
5'6AL A5T'5'S 6I5K5'6AL A5T'5'S 6I5K AB5TA 6I5K AB5TA 6I5K
6T'ST6AL A5T'5'S 6I5K6T'ST6AL A5T'5'S 6I5K
'T5'MTK A5T'5'S 6I5K'T5'MTK A5T'5'S 6I5K
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 53/55
7ardiac orm o atherosclerosis7ardiac orm o atherosclerosis
Acute orm occurs as myocardial inarction Acute orm occurs as myocardial inarction
or acute ischemic heart diseaseor acute ischemic heart disease
7hronic orm consists o chronic orms o7hronic orm consists o chronic orms oischemic heart diseaseischemic heart disease
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 54/55
3lood tests: used to evaluate kidney and thyroid function aswell as to check cholesterol levels and the presence ofanemia.
3)hest 56ray: shows the si7e of your heart and whether there
is 8uid build up around the heart and lungs.3%chocardiogram: shows a graphic outline of the heart9smovement
3%ection fraction %1;: determines how well your heartpumps with each beat.
7/23/2019 Dislipidemia Atherosclerosis
http://slidepdf.com/reader/full/dislipidemia-atherosclerosis 55/55
Many people are a)le to manageMany people are a)le to managecoronary artery disease -ith liestylecoronary artery disease -ith liestyle
changes and medicationschanges and medications
Bther people -ith se.ere coronaryBther people -ith se.ere coronary
artery disease may need angioplasty orartery disease may need angioplasty orsurgerysurgery